Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16307317 | 1.00 | CA1 (0.42) | CA1CA2FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16307305 | 0.89 | CA1 (0.42) | CA1CA2PTGS1PTGS2SOS1 | |
| SCHEMBL16290406 | 0.89 | CA1 (0.42) | CA1CA2PTGS1PTGS2SOS1 | |
| SCHEMBL18710482 | 0.88 | CA1 (0.46) | CA1CA2FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16290717 | 0.88 | CA1 (0.46) | CA1CA2FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16307308 | 0.77 | CA1 (0.46) | CA1CA2KMT2ATDP1ACLY | |
| SCHEMBL16307314 | 0.77 | CA1 (0.42) | CA1CA2FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16290393 | 0.77 | CA1 (0.42) | CA1CA2FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16307315 | 0.77 | CA1 (0.42) | CA1CA2FFAR1CYP2C8CYP2C9 | |
| SCHEMBL16290590 | 0.77 | CA1 (0.46) | CA1CA2KMT2ATDP1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865663-B1 | NOVEL INDANESULFAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | claimed |
| EP-2865663-A1 | NOVEL INDANESULFAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-04-29 | — | — | EP | claimed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | claimed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | claimed |
| EP-2865663-B1 | NOVEL INDANESULFAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2865663-A1 | NOVEL INDANESULFAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | SCN1A, SCN7A, SCN2A | CA1 219/4885CA2 315/4885FFAR1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.